Back to search

Article

Repurposing Oncology Drugs for Alzheimer’s: Multi-Omic Convergence Targeting Cell-Cycle, Proteostasis, Immunometabolism, and Senescence

2025-09-23

Abstract excerpt

Alzheimer's disease (AD), the predominant dementia etiology, imposes a $1.5 trillion global burden in 2025, exacerbated by inexorable failures in amyloid-tau-centric monotherapies amid <1% trial success rates. This review synthesizes cross-disciplinary pathobiology underpinning oncology drug repurposing for AD, leveraging inverse epidemiological antagonism and convergent hallmarks: aberrant neuronal cell-cycle...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5ac2dda9-64fc-523f-8316-0d1b46fae057
DOI
10.20944/preprints202509.1889.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Repurposing Oncology Drugs for Alzheimer’s: Multi-Omic Convergence Targeting Cell-Cycle, Proteostasis, Immunometabolism, and SenescenceDOI 10.20944/preprints202509.1889.v1
Rethinking Anti-Inflammatory Therapy in Alzheimer’s Disease: From Broad Suppression to Stage–State–Space Neuroimmune ReprogrammingSemantic proximity
Post-translational modifications in the brain are critical contributors to Alzheimer’s disease neuropathology and cognitive declineSemantic proximity
The Cepeda Framework: A Modular, Safety-First Preclinical Architecture for Testing Coordinated Multi-Hallmark Rejuvenation Hypotheses in Biological AgingSemantic proximity
Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer’s DiseaseSemantic proximity
"Amyloid-beta accumulation cycle" as a prevention and/or therapy target for Alzheimer's disease.Semantic proximity
Targeting dementias through cancer kinases inhibitionSemantic proximity
Dual Inhibitors Targeting G9a and GSK-3β: Translational Perspectives on Alzheimer’s Disease TreatmentSemantic proximity
Do Cancer Drugs Counteract Neurodegeneration? Repurposing for Alzheimer’s DiseaseSemantic proximity
The Alzheimer’s disease drug development landscapeSemantic proximity
Functional-vs-Cognitive Decline Heterogeneity in Alzheimer’s Disease: LLM-Curation of Decades of Clinical Notes and GLP1RA Trial DesignSemantic proximity
Restoring the epigenome in Alzheimer's disease: advancing HDAC inhibitors as therapeutic agentsSemantic proximity
From APOE Genetics to AI-Designed Drug Candidates: An Integrated Pipeline for Oral, Brain-Penetrant ACAT1 Inhibitors in Alzheimer’s DiseaseSemantic proximity
Select a neighboring publication to make it the new centre.